Miglustat capsules bulk supplier for pharma manufacturers

Miglustat Capsules 100 mg Suppliers & Bulk Manufacturers

Available Forms: Capsules

Available Strengths: 100 mg

Reference Brands: Zavesca(US)

Miglustat capsules inhibit glucosylceramide synthase, reducing the formation of glycosphingolipids that accumulate in Gaucher's and Niemann-Pick diseases. It slows disease progression, alleviates symptoms, and improves quality of life. Benefits include decreased organ size, enhanced motor function, and supportive long-term disease management.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Product Description: Miglustat capsules, marketed as Zavesca, are approved in the US by the FDA and in the EU via EMA for treating Gaucher’s disease type 1 and Niemann-Pick disease type C. Regulatory approval requires a detailed dossier including clinical efficacy, safety profiles, manufacturing standards, and pharmacovigilance plans. In the US, the FDA reviews comprehensive clinical trial and quality data for timely approval, while the EMA ensures compliance with regional safety, efficacy, and manufacturing regulations. For guidance on dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Proper regional adherence supports swift approval, safe use, and worldwide availability, aiding in management of rare metabolic disorders.

Miglustat Capsules — third party manufacturing & bulk supply

Miglustat Capsules 100 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Miglustat Capsules is supplied as Capsules — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Miglustat Capsules listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Miglustat Capsules →

Back to Listing

Frequently Asked Questions

Miglustat capsules is listed as Capsules in 100 mg. Further strengths and pack presentations are confirmed with the manufacturer at RFQ stage.

Miglustat capsules is referenced against Zavesca(US). Reference brands are shown for identification only and remain the property of their respective trademark owners.